A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs BL 8040 (Primary) ; Pembrolizumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms COMBAT
- Sponsors BioLineRx
- 08 Aug 2017 Top line results from this trial are expected in H2 2018 according to a BioLineRx media release.
- 22 Nov 2016 According to a BioLineRx media release, partial results from this study are expected by second half of 2017.
- 23 Sep 2016 Status changed from not yet recruiting to recruiting.